| Previous Close | 82.64 |
| Open | 82.73 |
| Bid | 82.60 x 400 |
| Ask | 83.00 x 200 |
| Day's Range | 82.23 - 83.41 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 6,194,703 |
| Avg. Volume | 10,050,717 |
| Market Cap | 107.9B |
| Beta | 0.91 |
| PE Ratio (TTM) | 8.97 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.53%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Motley Fool•7 hours ago
3 Biotech Stocks With Major Catalysts Incoming
Clinical trial results and FDA meetings expected in the near term could set these stocks up for big gains over the long run.
- Forbes•9 hours ago
Why Gilead Sciences Is Flying High With Kite
Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.
Markit•16 hours agoSee what the IHS Markit Score report has to say about Gilead Sciences Inc.
Gilead Sciences Inc NASDAQ/NGS:GILD
